2017年，珠海岐微生物科技股份有限公司在横琴注册，成为首批入驻园区的医药企业之一。公司主要针对全球尚无有效药物的眼科重大疾病——干性老年黄斑变性，开发创新中药和小分子化学药品。目前，公司的创新中药QA108在国内已进入Ⅲ期临床试验。公司首席技术官欧阳晖说：“关于老年黄斑变性致病机理研究的论文已在国际医学杂志上发表，为新药问世奠定了坚实基础。这款新药将填补全球空白，造福更多老年黄斑变性患者。”
Gold 'three lions' pendant from the 13th-14th Century
，推荐阅读51吃瓜获取更多信息
Yesterday, Axios reported that Hegseth gave Anthropic a deadline of 5:01 PM on Friday to agree to the Pentagon's terms. At the same time, the DoD requested an assessment of its reliance on Claude, an initial step toward potentially labelling Anthropic as a "supply chain risk" — a designation usually reserved for firms from adversaries like China and "never before applied to an American company," Anthropic wrote.
更多详细新闻请浏览新京报网 www.bjnews.com.cn